$ALKS

Alkermes plc.

Alkermes is an Ireland-headquartered global biopharmaceutical company focused on developing medicines in neuroscience. It develops and commercializes treatments for schizophrenia, bipolar I disorder, narcolepsy, alcohol dependence and opioid dependence, and has development programs for neurological disorders. Its proprietary U.S. products include ARISTADA and ARISTADA INITIO for schizophrenia, LYBALVI for schizophrenia and bipolar I disorder, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. Alkermes earns money by selling its own products and by receiving royalties, manufacturing payments and other revenues from products commercialized by licensees. These include Janssen’s long-acting INVEGA products and RISPERDAL CONSTA, which Alkermes manufactures, and Biogen’s VUMERITY. The company also develops and licenses drug-delivery technologies, including injectable extended-release, LINKERX, NANOCRYSTAL and MICROPUMP platforms. Its facilities include a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.

1
3
1
—
$94K
Gaffin David Joseph
100%
See all $ALKS insider activity →
Low

Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead

Alkermes (ALKS) CEO Richard Jackson announced six clinical readouts expected in the next 12 months, including Phase 3 studies for narcolepsy and a Phase 2 study for ADHD drug ALKS 7290. The company also expects to file LUMRYZ, its narcolepsy treatment, and discussed its commercial strategy for VIVITROL and LYBALVI, citing patent protection and manufacturing challenges for potential competitors.

Alkermes and Teva Resolve LYBALVI Patent Litigation

Alkermes (ALKS) and Teva settled patent litigation over LYBALVI. The agreement resolves all dosage strengths and dismisses the lawsuit. ALKS has a $50 price target and is rated Hold. Spark's AI rates it Neutral, citing weak profitability but solid cash flow and pipeline progress.

Alkermes plc. (ALKS): Entry into a Material Definitive Agreement

Alkermes plc. (ALKS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreeme

ALKS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ALKS (Alkermes plc.). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.

Recent ALKS coverage spans financial news, earnings and corporate actions.

In the last 30 days, ALKS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($94K). The most active reporter was Gaffin David Joseph, EVP, CLO, Alkermes, Inc., with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ALKS

AlphAI scores every news story that mentions ALKS with an AI model for sentiment and relevance, and aggregates insider trades from Alkermes plc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ALKS

Score

Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead

Alkermes (ALKS) CEO Richard Jackson announced six clinical readouts expected in the next 12 months, including Phase 3 studies for narcolepsy and a Phase 2 study for ADHD drug ALKS 7290. The company also expects to file LUMRYZ, its narcolepsy treatment, and discussed its commercial strategy for VIVITROL and LYBALVI, citing patent protection and manufacturing challenges for potential competitors.

$ALKSLowContract

Alkermes plc. (ALKS): Entry into a Material Definitive Agreement

Alkermes plc. (ALKS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreeme

Alkermes CEO Blair Jackson Bets Six Readouts and a 70% Sleepiness Benchmark on Orexin — BigGo Finance

Alkermes CEO Blair Jackson prioritizes operational execution, with six clinical studies expected in the next year. The most critical is a Phase 2 study for idiopathic hypersomnia, aiming for a 70% improvement in sleepiness. Jackson aims to compete with Takeda's orexin drug by offering more dosing options and combinations with Lumryz. The company focuses on funding existing catalysts and small deals to fill pipeline gaps.

H.C. Wainwright raises Alkermes stock price target to $50 on pipeline progress

H.C. Wainwright raised its price target for Alkermes (ALKS) to $50 from $43, citing progress in its clinical pipeline and commercial revenue. The stock is up 63% year-to-date. The firm maintained a Neutral rating. Alkermes recently reported stronger-than-expected Q3 2026 results, with adjusted earnings of $0.09 per share and revenue of $480.1 million. Baird and Wells Fargo also raised their price targets.

$ALKSHighAI 8/10Earnings

Alkermes plc Reports Third Quarter 2026 Financial Results

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2026 Financial Results — Third Quarter Revenues of $480.1 Million — — GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120

Related tickers